# Roivant

**Canonical:** https://apis.io/providers/roivant/  
**Website:** https://roivant.com  
**APIs profiled:** 0

Roivant Sciences Ltd. (Nasdaq: ROIV) is a commercial-stage biopharmaceutical holding company that accelerates the development and commercialization of medicines through its distinctive "Vant" model, a network of nimble, focused subsidiary companies such as Immunovant, Priovant, and Pulmovant. Founded in 2014, Roivant advances a pipeline spanning immunology, dermatology, and other therapeutic areas, and has delivered multiple FDA approvals and Phase 3 trial successes. Roivant is a company profile in the API Evangelist network; it operates a corporate and investor web presence but publishes no public developer API surface.

## Kin Score — 9.3 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 9.3).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 1.2 |
| Commercial Clarity | 21.1 |
| Access Clarity | 21.1 |

Regulatory layer — **Health**: 17.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Roivant Domain Security** — TLSv1.3 · HSTS · DMARC

## Tags

Company, Health Tech, Biopharmaceutical, Pharmaceuticals, Drug Development, Life Sciences, Immunology

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/roivant/). Scores are computed from the provider's own public artifacts under a published rubric.